Publicaciones

Publicaciones de los últimos siete años:

• Berdasco M, Gómez A, Rubio MJ, Català-Mora J, Zanón-Moreno V, Lopez M, et al. DNA Methylomes Reveal Biological Networks Involved in Human Eye Development, Functions and Associated Disorders. Sci Rep. 2017;7(1):11762. doi: 10.1038/s41598-017-12084-1.
• Katschnig AM, Kauer MO, Schwentner R, Tomazou E, Mutz CN, Linder M, et al. EWS-FLI1 perturbs MRTFB/YAP-1/TEAD target gene regulation inhibiting cytoskeletal auto-regulatory feedback in Ewing sarcoma. Oncogene. 2017:doi: 10.1038/onc.2017.202
• Schwentner R, Herrero-Martín D, Kauer MO, Mutz CN, Katschnig AM, Sienski G, et al. The role of miR-17-92 in the mi Regulatory landscape of Ewing sarcoma. Oncotarget. 2017;8(7):10980-93.
  
• Mutz CN, Schwentner R, Aryee DNT, Bouchard EDJ, Mejia EM, Hatch GM, et al. EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells. Oncotarget. 2017;8(15):24679-93.
• Huertas-Martínez J, Court F, Rello-Varona S, Herrero-Martín D, Almacellas-Rabaiget O, Sainz-Jaspeado M, et al. DNA methylation profiling identifies PTRF/Cavin-1 as a novel tumor suppressor in Ewing sarcoma when co-expressed with caveolin-1. Cancer letters. 2017;386:196-207.
• He T, Surdez D, Rantala JK, Haapa-Paananen S, Ban J, Kauer M, et al. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability. Gene. 2017;596:137-46.
• Cidre-Aranaz F, Grunewald TG, Surdez D, Garcia-Garcia L, Carlos Lazaro J, Kirchner T, et al. EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma. Oncogene. 2017;36(6):766-76.
• Bardon-Cancho EJ, Haro-Díaz A, Alonso-Garcia-de la Rosa FJ, Huerta-Aragones J, Garcia-Morin M, González-Martinez F, et al. DICER1 mutation and tumors associated with a familial tumor predisposition syndrome: practical considerations. Fam Cancer. 2017;16(2):291-4.
• Ruiz-Pinto S, Pita G, Patino-García A, Garcia-Miguel P, Alonso J, Perez-Martinez A, et al. Identification of genetic variants in pharmacokinetic genes associated with Ewing Sarcoma treatment outcome. Annals of oncology 2016;27(9):1788-93.
• Rodriguez-Martin C, Cidre F, Fernandez-Teijeiro A, Gómez-Mariano G, de la Vega L, Ramos P, et al. Familial retinoblastoma due to intronic LINE-1 insertion causes aberrant and noncanonical mRNA splicing of the RB1 gene. J Hum Genet. 2016.
• Nieto-Soler M, Morgado-Palacín I, Lafarga V, Lecona E, Murga M, Callen E, et al. Efficacy of ATR inhibitors as single agents in Ewing sarcoma. Oncotarget. 2016;7(37):58759-67.
• Mutz CN, Schwentner R, Kauer MO, Katschnig AM, Kromp F, Aryee DN, et al. EWS-FLI1 impairs aryl hydrocarbon receptor activation by blocking tryptophan breakdown via the kynurenine pathway. FEBS letters. 2016;590(14):2063-75.
• Grünewald TGP, Bernard V, Gilardi-Hebenstreit P, Raynal V, Surdez D, Aynaud M-M, et al. Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite. Nature Genetics. 2015;47(9):1073-+.
• Cidre-Aranaz F, Alonso J. EWS/FLI1 Target Genes and Therapeutic Opportunities in Ewing Sarcoma. Frontiers in oncology. 2015;5:162.
• Lara B, Teresa Martinez M, Blanco I, Hernandez-Moro C, Velasco EA, Ferrarotti I, et al. Severe alpha-1 antitrypsin deficiency in composite heterozygotes inheriting a new splicing mutation QOMadrid. Respiratory Research. 2014;15:125
• Agra N, Cidre F, Garcia-Garcia L, de la Parra J, Alonso J. Lysyl Oxidase Is Downregulated by the EWS/FLI1 Oncoprotein and Its Propeptide Domain Displays Tumor Supressor Activities in Ewing Sarcoma Cells. Plos One. 2013;8(6).
• Postel-Vinay S, Veron AS, Tirode F, Pierron G, Reynaud S, Kovar H, et al. Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. Nat Genet. 2012;44(3):323-7.
• Kovar H, Alonso J, Aman P, Aryee DN, Ban J, Burchill SA, et al. The first European interdisciplinary ewing sarcoma research summit. Front Oncol. 2012;2:54.
• Serrano C, Alonso J, Gómez-Mariano G, Aguirre E, Diéz O, Gadea N, et al. Low penetrance hereditary retinoblastoma in a family: what should we consider in the genetic counselling process and follow up?. Familial Cancer. 2011;10:617-621.
• Kontic M, Palacios I, Kontic M, Alonso J, Pestaña A. Linkage analysis and detection of somatic, postzygous RB1 mutations in Serbian retinoblastoma patients. Journal of BUON. 2011;16:142-146.
• Lalli E., Alonso J. Targeting DAX-1 in embryonic stem cells and cancer. Expert Opin. Ther. Targets. 2010;14:169-177
• Navarro D, Agra N, Pestaña A, Alonso J, González-Sancho J. The EWS/FLI1 oncogenic protein inhibits expression of the Wnt inhibitor DICKKOPF-1 gene and antagonizes β-catenin/TCF-mediated transcription. Carcinogenesis. 2010;3:394-401.
• Gómez-Cabello D, Callejas S, Benguría A, Moreno A, Alonso J, Palmero I. Regulation of the microRNA processor DGCR8 by the tumor suppressor ING1. Cancer Res. 2010;70(5):1866-74.